Join LES USA-Canada's Life Sciences Sector and the Boston Chapter for two informative panels that will discuss structuring life sciences transactions and key issues for biopharma licensing deals.
Panel 1: Structuring Your Life Sciences Transaction in 2026: Licensing vs. M&A vs. Options to Buy vs. Asset Sale
Topics to be covered include:
- Key considerations when structuring your life sciences deal
- Deal trends – the emergence of options to buy
- How to determine when you should do a M&A deal, a license, an option to buy, or an asset sale?
- Strategies for doing deals with big pharma
- What does big pharma look for in a deal structure?
- Is licensing a way to a M&A deal with a big pharma partner?
Panel 2: Navigating Licensing Deals Involving Chinese Life Sciences Assets: Strategies, Challenges, and Opportunities
Topics to be covered include:
- Key regulatory and legal frameworks governing deals involving Chinese life sciences assets, and how they differ from Western jurisdictions
- How to approach due diligence when evaluating potential Chinese licensees or licensors
- Common deal structures for China licensing transactions, including territory splits, milestone payments, and royalty arrangements
- Cultural factors and negotiation styles that impact deal-making with Chinese counterparties
- IP protection strategies and navigating CFIUS, export controls, and other cross-border regulatory considerations
- Emerging trends in deals involving Chinese life sciences assets, including the rise of Chinese biotechs as licensors of innovative therapies
